The deal allows Mullis to become the chief scientific officer and Charles Roberts, CEO of Loxbridge, takes on the role of president of Altermune for the initial developmental period.
Loxbridge CEO Roberts said the Altermune project provides a platform of therapeutic opportunities against a range of pathogens, with some compelling preclinical proof of concept.
"We will be investigating each candidate in a research program before focusing on one or more lead candidates to progress to the clinic," Roberts said.